Organogenesis (ORGO) Q2 2026 Earnings Call Transcript
Organogenesis (ORGO) reported Q2 2026 revenue down 58% year over year, driven by a 61% drop in Advanced Wound Care sales. Net product revenue rose 18% quarter over quarter. The company cited CMS coverage changes as slowing recovery, announced a June restructuring with 138 job cuts and about $18M annualized cost savings, and updated 2026 revenue guidance. It also cited DFU and venous ulcer study results and FDA acceptance of Amnuvx BLA with a PDUFA date of Apr 24, 2027.
How this was made
The 30-second read
Why it matters
The company attributes Q2 weakness to slower market recovery from CMS reforms, then updates 2026 revenue expectations to reflect a more measured recovery pace. It also details cost actions (June restructuring) and provides clinical and regulatory progress for PuraPly AM, Affinity, and Amnuvx (FDA accepted BLA, PDUFA target April 24, 2027).
Market read
Traders get a same-day reset of 2026 revenue expectations tied to CMS-driven reimbursement dynamics, plus a longer-dated but concrete FDA timeline for Amnuvx.
What to watch
Investors may be underweighting the evidence pipeline (PuraPly AM and Affinity RCT/publications) and the Amnuvx FDA acceptance, which could improve coverage prospects even if near-term revenue remains depressed.
Background
Organogenesis’ skin substitute business is described as having been hit by CMS coverage and payment reforms announced in late December 2025, with additional discussion of proposed OPPS and physician fee schedule changes.
Ticker impact
Organogenesis reports Q2 revenue down 58% YoY, cites CMS-driven skin substitute contraction, and updates 2026 revenue guidance after restructuring.
Bias to downside or volatility until investors see evidence of faster post-CMS stabilization and clarity on Amnuvx approval path.
The call discloses large YoY revenue contraction, a June restructuring with ongoing guidance reset, and FDA acceptance with a PDUFA target in 2027, which is supportive but not an immediate earnings catalyst.
Market effects
CMS coverage and payment changes are framed as the key driver of demand contraction, implying broader read-through risk for skin substitute peers reliant on similar reimbursement pathways.
Primarily US reimbursement-driven, with Medicare beneficiary outcomes highlighted for wound-care adoption.
Limited direct global impact; US payer policy is the dominant variable in the narrative.
Counterpoint
Sequential net product revenue growth and expanding unit volume could indicate the worst of the CMS shock is already passing, making the guidance reset more conservative than deteriorating fundamentals.
Key entities
- companyOrganogenesis
Reports Q2 2026 results, updates 2026 revenue guidance, and discusses restructuring and clinical/regulatory milestones.
- regulatorCMS
US Centers for Medicare and Medicaid Services, cited as driving skin substitute market contraction via coverage and payment changes.
- regulatorFDA
US Food and Drug Administration, cited for accepting the Amnuvx BLA and setting a PDUFA target date.
